Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemiaRobert S Rosenson
Preventive Cardiology Center, Department of Medicine, Division of Cardiology, Northwestern University, The Feinberg School of Medicine, Galter Pavilion, Suite 11 120, 201 East Huron Street, Chicago, IL 60611, USA
Atherosclerosis 185:327-30. 2006
..The effect of colesevelam HCl on LDL particle number and particle size has not been previously published. LDL particle number and particle size were measured by NMR spectroscopy...
- Short-term reduction in bone markers with high-dose simvastatin
Robert S Rosenson
Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, Northwestern University, Feinberg School of Medicine, 301 E Huron Street, Galter Pavilion, Chicago, IL 60611, USA
Osteoporos Int 16:1272-6. 2005
..Short-term use of high-dose simvastatin lowers the level of the serum bone marker bone-specific alkaline phosphatase, which suggests the possibility of reduced bone turnover...
- Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects
Robert S Rosenson
Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
J Lab Clin Med 145:83-7. 2005
..46, P = .0056) in statin-treated subjects. Statin therapy reduced MCP-1 production in the whole blood of human subjects and these changes were correlated with improvement in LDL oxidative resistance...
Management of non-high-density lipoprotein abnormalitiesRobert S Rosenson
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
Atherosclerosis 207:328-35. 2009
..Improvement in lipid control and reduction in atherogenic risk could be anticipated to translate to benefits in clinical outcomes...
- Statins: can the new generation make an impression?
Robert S Rosenson
Northwestern University, Preventive Cardiology Center, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
Expert Opin Emerg Drugs 9:269-79. 2004
..Results of a number of outcome studies with rosuvastatin are expected over the next 5 years, which will contribute to the evidence base for statin therapy and cardiovascular disease prevention...
- Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients
Robert S Rosenson
Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
Obesity (Silver Spring) 17:504-9. 2009
..Changes in adiponectin were significantly and inversely associated with changes in multiple inflammatory markers. These data suggest that adiponectin may contribute to the anti-inflammatory effects of fenofibrate...
- Biomarkers, atherosclerosis and cardiovascular events
Robert S Rosenson
Department of Medicine, University of Michigan, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106, USA
Expert Rev Cardiovasc Ther 6:619-22. 2008
..It was attended by nearly 30,000 participants from around the world. The conference was highlighted by the presentation of 13 late-breaking clinical trials and 13 late-breaking abstracts...
- Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, Chicago, IL, USA
Am Heart J 151:556-63. 2006
..Extending statin therapy to patients with low levels of HDL-C but with LDL-C levels below target may have benefits for cardiovascular disease reduction in these patients...
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trialMichael Davidson
Radiant Research, Chicago, IL 60610, USA
Cardiovasc Drugs Ther 26:349-58. 2012
....
- Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production
Robert S Rosenson
Department of Medicine, SUNY Downstate, Brooklyn, NY 11203, USA
Cardiovasc Drugs Ther 23:289-94. 2009
..Despite these putative mechanisms, amlodipine is equally efficacious as other therapies in reducing cardiovascular events...
- Assessing risk across the spectrum of patients with the metabolic syndrome
Robert S Rosenson
Preventive Cardiology Center, Division of Cardiology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Am J Cardiol 96:8E-10E. 2005
..Risk assessment models for patients with the metabolic syndrome should consider inclusion of LDL particle number, inflammatory markers, and levels of plasminogen activator inhibitor-1...
- Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia
Robert S Rosenson
Department of Medicine, Division of Cardiology, Preventive Cardiology Center, The Feinberg School of Medicine, Northwestern University, 201 East Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
Atherosclerosis 177:77-81. 2004
..048). A high level of sTNFRSF1B is a strong marker of the pro-inflammatory state in this sample of male ADL subjects...
- Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Galter Pavilion 11 120, 201 East Huron Street, Chicago, IL 60611, USA
Curr Opin Cardiol 20:313-7. 2005
..Discuss the contribution of low-density lipoprotein subclass abnormalities to cardiovascular risk among individuals with low high-density lipoprotein cholesterol levels...
- Antiatherothrombotic effects of nicotinic acid
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion 11 120, Chicago, IL 60612, USA
Atherosclerosis 171:87-96. 2003
..By preserving glycolysis during periods of ischemia and improving subendocardial blood flow during reperfusion, niacin can improve the functional recovery of the myocardium...
- Low HDL-C: a secondary target of dyslipidemia therapy
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, Chicago, Ill 60611, USA. r-rosenson.northwestern.edu
Am J Med 118:1067-77. 2005
..Although lowering LDL-C remains the primary target of lipid-modifying therapy, dyslipidemia therapies that are efficacious for both LDL-C reduction and raising HDL-C might offer further improvements in CHD risk reduction...
- Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion, Chicago, IL 60611, U S A
Clin Sci (Lond) 106:215-7. 2004
..In contrast with the known effects of oxidized LDL on gene activation of ICAM-1 and VCAM-1, lag times did not correlate with sICAM-1 and sVCAM-1. Statin therapy improved lag times, but has no effect on sICAM-1 or sVCAM-1 levels...
- An assessment of statin safety by muscle experts
Paul D Thompson
Division of Cardiology, Hartford Hospital, Hartford, Connecticut 06102, USA
Am J Cardiol 97:69C-76C. 2006
..The panel was composed of a clinical cardiologist, an exercise physiologist and skeletal muscle expert, and an expert in preventive cardiology who also examined skeletal muscle complications of statin use...
- Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day
Robert S Rosenson
Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Am J Cardiol 91:878-81. 2003
- HDL-C and the diabetic patient: target for therapeutic intervention?
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion Suite 11 120, Chicago, IL 60611, USA
Diabetes Res Clin Pract 68:S36-42. 2005
..Selecting an agent that will increase HDL-C levels, as well as lowering LDL-C levels, may be particularly beneficial in the treatment of patients with the metabolic syndrome and type 2 diabetes...
- Novel targets that affect high-density lipoprotein metabolism: the next frontier
Michael H Davidson
University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
Am J Cardiol 104:52E-7E. 2009
..This article reviews current options for the therapeutic management of HDL cholesterol, including discussion of novel agents aimed at reducing cardiovascular disease risk in patients with low levels of HDL cholesterol...
- New approaches in the intensive management of cardiovascular risk in the metabolic syndrome
Robert S Rosenson
Department of Medicine, Northwestern University, Feinberg School of Medicine, USA
Curr Probl Cardiol 30:241-79. 2005
..A multifaceted approach to risk factor management for the metabolic syndrome will have benefits for prevention of type 2 diabetes and cardiovascular disease...
- Current overview of statin-induced myopathy
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
Am J Med 116:408-16. 2004
..Drug-drug interactions may be avoided by selecting a statin that does not share the same metabolic pathway...
- Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
Atherosclerosis 173:1-12. 2004
..It may be that the ability of statins to limit the oxidation of LDL contributes to their effectiveness at preventing atherosclerotic disease...
- Modulating atherosclerosis through inhibition or blockade of angiotensin
Robert S Rosenson
Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
Clin Cardiol 26:305-11. 2003
..This article reviews some of the biologic mechanisms whereby ACE inhibitors and ARBs may modulate atherosclerosis...
- Utility of inflammatory markers in the management of coronary artery disease
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
Am J Cardiol 92:10i-8i. 2003
..Some fibrates decrease fibrinogen levels and hs-CRP. Statin therapy either reduces the CAD risk associated with system inflammation or lowers circulating levels of hs-CRP...
- Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia
Robert S Rosenson
Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, IL 60611, USA
Expert Rev Cardiovasc Ther 1:495-505. 2003
..Rosuvastatin is well tolerated, with a safety profile comparable with that of other currently available statins...
- Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes
Robert S Rosenson
Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Curr Opin Cardiol 19:480-7. 2004
..This article reviews evidence that treatments directed at the individual components of the metabolic syndrome will delay the progression to type 2 diabetes and will reduce the incidence of cardiovascular disease...
- The rationale for combination therapy
Robert S Rosenson
Department of Medicine and Preventive Medicine, Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
Am J Cardiol 90:2K-7K. 2002
..This article reviews the rationale for the use of combination therapy in the treatment of dyslipidemia, highlighting management strategies...
- Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial
Robert S Rosenson
Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
Am J Cardiol 90:89-94. 2002
..01) in the placebo group. These results indicate that levels of various lipoprotein subclasses may provide useful information on CAD risk even if levels of traditional risk factors are known...
- Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity
Robert S Rosenson
Lipoprotein and Hemorheology Research Facility, Section of Cardiology, Department of Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
Atherosclerosis 161:433-9. 2002
..This study supports an additional mechanism whereby triglycerides may contribute to cardiovascular risk...
- Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
Scott M Grundy
The University of Texas Southwestern Medical Center, Room Y3206, 5323 Harry Hines Blvd, Dallas, TX 75390-9052
Arch Intern Med 162:1568-76. 2002
..No hepatotoxic effects or myopathy were observed. CONCLUSION: Low doses of ER niacin (1000 or 1500 mg/d) are a treatment option for dyslipidemia in patients with type 2 diabetes...
- Effect of methyl testosterone administration on plasma viscosity in postmenopausal women
Shehzad Basaria
Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Clin Endocrinol (Oxf) 57:209-14. 2002
..The combination regimen did not result in major side-effects. Based on these results, we feel confident in recommending low-dose androgens to postmenopausal women with a history of sexual dysfunction and decreased libido...
- Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
Robert S Rosenson
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI 48106 0636, USA
Am Heart J 155:499.e9-16. 2008
..Fenofibrate reduces Lp-PLA2 mass; however, it remains unknown whether the anti-inflammatory effects of fenofibrate are related to changes in LDL subclasses...
- Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome
Robert S Rosenson
Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106 0736, USA
Atherosclerosis 198:381-8. 2008
..To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia...
- Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus
Robert S Rosenson
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48106 0363, USA
Am J Cardiol 99:96B-104B. 2007
..Future studies of PPAR-gamma agonists or dual PPAR-alpha/gamma agonists will require further delineation of the risk profile to avoid adverse outcomes in susceptible patients...
- Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study
Lawrence A Leiter
Division of Endocrinology and Metabolism, St Michael s Hospital, University of Toronto, Toronto, Canada
Atherosclerosis 194:e154-64. 2007
..Rosuvastatin may therefore improve LDL-C goal achievement in high-risk patients with hypercholesterolemia...
- Field of confusion: future prospects for fibrate therapy in cardiovascular disease
Robert S Rosenson
Curr Atheroscler Rep 8:219-22. 2006
- Statin therapy: new therapy for cardiac microvascular dysfunction
Robert S Rosenson
Eur Heart J 24:1993-4. 2003
- Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial
James D Otvos
Department of Biochemistry, North Carolina State University, Raleigh, NC, USA
Atherosclerosis 160:41-8. 2002
....
